To study the occurrence of inhibitors in children affected with hemophilia ‘A’ and hemophilia ‘B’ disease

  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
  • strict warning: Declaration of content_handler_field::options() should be compatible with views_object::options() in /home4/vibu/public_html/journalcra.com/sites/all/modules/cck/includes/views/handlers/content_handler_field.inc on line 208.
  • strict warning: Declaration of views_handler_filter::options_validate() should be compatible with views_handler::options_validate($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_handler_filter::options_submit() should be compatible with views_handler::options_submit($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter.inc on line 589.
  • strict warning: Declaration of views_plugin_style_default::options() should be compatible with views_object::options() in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_style_default.inc on line 25.
  • strict warning: Declaration of views_plugin_row::options_validate() should be compatible with views_plugin::options_validate(&$form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Declaration of views_plugin_row::options_submit() should be compatible with views_plugin::options_submit(&$form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/plugins/views_plugin_row.inc on line 135.
  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
  • strict warning: Declaration of views_handler_filter_boolean_operator::value_validate() should be compatible with views_handler_filter::value_validate($form, &$form_state) in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/handlers/views_handler_filter_boolean_operator.inc on line 149.
  • strict warning: Non-static method view::load() should not be called statically in /home4/vibu/public_html/journalcra.com/sites/all/modules/views/views.module on line 842.
Author: 
Dr. Sandeep Kumar and Dr. Manju Kumari
Subject Area: 
Health Sciences
Abstract: 

Introduction: Use of factor VIII and factor IX concentrates has decreased the morbidity and mortality in patients with hemophilia. But with increasing use of factor concentrates, one major complication occurring is formation of inhibitors to Factor VIII and Factor IX which results in poor response to factor administration making control of hemorrhages more difficult. Different studies show enormous difference in inhibitor occurrence. The prevalence of inhibitors is estimated to be between 5 and 10% of all hemophilia A with 20% of severe hemophilia A patients and 3–5% of all hemophilia B patients Aim of study: To study the occurrence of inhibitors in hemophilia A and hemophilia B affected children receiving factor replacement therapy. Material and Methods: The study was conducted in department of pediatrics, S.M.S. medical College, jaipur, India from april 2011 to March 2013 and a total of 100 children with hemophilia were screened for inhibitors to factor VIII and IX with quantification done by Bethesda assay. Results: Out of 100 hemophilia children screened 81(81.00%) had hemophilia A and 19 (19.00%) had hemophilia B. Among 81 Hemophilia A patients, 56 (69.14%) had severe, 13 (16.05%) had moderate and 12 (14.81) had mild hemophilia A disease. Among 19 hemophilia B patients, 15 (78.95%) and 4 (21.05%) had severe and moderate hemophilia B respectively. 4 patients, all belonging to severe hemophilia A, were found to be inhibitor positive. Thus 4.94% (4 out of 81) of total hemophilia A and 7.14% (4 out of 58) of severe hemophilia A patients were found inhibitor positive. None of the 19 hemophilia B patients showed inhibitors. Inhibitor titers ranged from 3.1 BU/mL to 128 BU/mL. Conclusions: Percentage of patients showing inhibitor positivity is slightly lesser than previous studies. Inhibitor occerrance in still low in Indian patients than their western counterparts. However,with increasing use of factor concentrates in hemophiliac children in developing setups, inhibitor occurrence is expected to increase and screening at regular intervals advised , to detect inhibitors early.

PDF file: 

Editorial Board Member's

Dr.Geetanjali Joshi Mishra
Lucknow, UP, INDIA
Dr. Sankalp Verma
India
Tannu Arora
India
Prof Dr. Lee Mun Seng
Malaysia
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
Dr. Lim Gee Nee
Malaysia
DANA MOHAMMED
UK
Ali Majnoony Tootakhaneh
Iran
Prof. Somchai Amornyotin
Thailand
Nurhodja Akbulaev
Turkey
Muhammad Hamid
Pakistan
MOHAMMAD GHOLAMI
Iran
MAVLYANOV ISKANDAR RAKHIMOVICH
Uzbekistan
Hasan Ali Abed Al-Zu’bi
Jordan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Eapen, Asha Sarah
USA
Dr. Ruchika Khanna
India
DR. MUHAMMAD ISMAIL MOHMAND
UK
DR. MAHESH SHIVAJI CHAVAN
India
Dr. Lokesh Gambhir
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Charu Bisaria
India
Dr. Achmad Choerudin
Indonesia
Bensafi Abd-El-Hamid
Algeria
Dr. Pralhad Kanhaiyalal Rahangdale
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Arun Kumar
India
DR. M. ARUNA
India
ALIIHSAN SEKERTEKIN
Turkey
Yassine KADMI
French
Tariqual Islam Sajeeb
Dhaka
Jiban Shrestha
Nepal
Fredrick OJIJA
Tanzanian
Dr. Rasha Ali Eldeeb
Egypt
DR. PATRICK D. CERNA
Philippines
Dr. Amzad Basha Kolar
India
Prof. Suhail Hussein Al-Fatlawi
Iraq
ZiedIBN El Hadj
Tunisia
Zafer Omer Ozdemir
Turkey
Uthumporn Utra
Malasiya
Tarek Habeeb Ramadan Ahmed
Egypt
Syed Abdul Rehman Khan
China
Sri. P.C. Puri
India
Dr. Mohd Ramzi Bin Mohd Hussain
Malasiya
Peter Changilwa Kigwilu
Africa
P. Rajasulochana
India
Nam Nguyen Dang
Vietnam
Lachachi Abdelheq
Algerie
Ibrahim Khider Ibrahim Osman
Sudan
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Elsadig Gasoom FadelAlla Elbashir
Sudan
Dr. Zafar Iqbal
Pakistan
DR. Yogesh Dnyandeo Narkhede
India
Dr. Recep TAS
Turkey
Dr. Mustafa Y.G. Younis
Libiya
Dr. Ashok Kumar
India
Arshad Mehmood
Pakistan
Anania B. Aquino
Phillippines
Ahmed I.S. Ahmed
Egypt
Yaling Lin
Taiwan
Souhir Neifar
Tunisia
Nihad Abdel Latif Ali Kadhim
Iraq
Muhammad Aslam
Pakistan
Dr. Shahera S.Patel
India
Dr. Nicolas Padilla-Raygoza
Mexico
Dr. Jatinder Pal Singh Chawla
India
Dr. Devendra Kumar Gupta
India
Diones Krinski
Brasil
Aberham Kebedom Darge
Ethiopia
Atiya Firdous
Pakistan
Prof. Marco Nemesio E.Montano
Phillippines
Prof. Zora Singh
AUSTRALIA
Dr. Alaa Fahmy Mohamed
Egypt
Moataz Mostafa El-Nahas Ali El-sherbini
Egypt
Prof. M. Abdul Mottaleb
Maryville
Dr. Ali Seidi
Iran